ERBB2 and cancer: Therefore, a small number of cancer cells or a difference in the activity of tissue metalloproteinase in metastatic ALNs may result in variability in our FNA-HER2 measurements, which could lead to a FNA-HER2 discordance with the HER2 status of the corresponding primary breast cancer.